Regenxbio

RGNXNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$554.198 M

$10.72 -4.96%

Close of 7 Aug 2026

Revenue

$170.4M

#2354 by revenue

Earnings

-$193.9M

Loss-making

Shares outstanding

66,013,192

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#63Autolus TherapeuticsAUTL$561.6M
#64Prime MedicinePRME$556.3M
#65RegenxbioRGNX$554.2M
#66Artiva BiotherapeuticsARTV$550.9M
#67Eikon TherapeuticsEIKN$502.9M

Where these numbers come from

Share counts and financials for Regenxbio are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.